{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:40:05Z","timestamp":1750131605754,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40801-025-00495-w","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:29:23Z","timestamp":1748572163000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab"],"prefix":"10.1007","volume":"12","author":[{"given":"Karen","family":"Blitz-Shabbir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee M.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-303X","authenticated-orcid":false,"given":"Hina","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-5572","authenticated-orcid":false,"given":"Flavia","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-944X","authenticated-orcid":false,"given":"Suma","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Belviso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0153-4218","authenticated-orcid":false,"given":"Boyang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinyee","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"495_CR1","unstructured":"MS International Federation. New prevalence and incidence data now available in the Atlas of MS. 2023. https:\/\/www.msif.org\/news\/2023\/08\/21\/new-prevalence-and-incidence-data-now-available-in-the-atlas-of-ms\/. Accessed 20 Sep 2024."},{"key":"495_CR2","unstructured":"National Multiple Sclerosis Society. MS Prevalence. 2024. https:\/\/www.nationalmssociety.org\/about-the-society\/who-we-are\/research-we-fund\/ms-prevalence. Accessed 1 Jan 2025."},{"key":"495_CR3","doi-asserted-by":"crossref","unstructured":"Moore MZ, P\u00e9rez CA, Hutton GJ, Patel H, Cuascut FX. Health disparities in multiple sclerosis among Hispanic and Black populations in the United States. Biomedicines. 2023;11(4):1227.","DOI":"10.3390\/biomedicines11041227"},{"issue":"18","key":"495_CR4","doi-asserted-by":"publisher","first-page":"e1818","DOI":"10.1212\/WNL.0000000000200151","volume":"98","author":"AM Langer-Gould","year":"2022","unstructured":"Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology. 2022;98(18):e1818\u201327.","journal-title":"Neurology"},{"issue":"7","key":"495_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle M, Culpepper WJ, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurol. 2023;80(7):693\u2013701.","journal-title":"JAMA Neurol"},{"key":"495_CR6","doi-asserted-by":"crossref","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:100252.","DOI":"10.1016\/j.lana.2022.100252"},{"issue":"12","key":"495_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jamaneurol.2021.3416","volume":"78","author":"L Amezcua","year":"2021","unstructured":"Amezcua L, Rivera VM, Vazquez TC, Baezconde-Garbanati L, Langer-Gould A. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: a review. JAMA Neurol. 2021;78(12):1515\u201324.","journal-title":"JAMA Neurol"},{"issue":"4","key":"495_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ene.13571","volume":"25","author":"MO Alsaeed","year":"2018","unstructured":"Alsaeed MO, Harding KE, Williams OH, Willis MD, Hrastelj J, Tallantyre EC, et al. Multiple sclerosis: long-term outcomes in ethnic minorities. Analysis of a UK population-based registry. Eur J Neurol. 2018;25(4):701\u20134.","journal-title":"Eur J Neurol"},{"key":"495_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105153","volume":"81","author":"G Mallawaarachchi","year":"2024","unstructured":"Mallawaarachchi G, Rog DJ, Das J. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis. Mult Scler Relat Disord. 2024;81: 105153.","journal-title":"Mult Scler Relat Disord."},{"key":"495_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103248","volume":"56","author":"CA P\u00e9rez","year":"2021","unstructured":"P\u00e9rez CA, Lincoln JA. Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: a comparative study. Mult Scler Relat Disord. 2021;56: 103248.","journal-title":"Mult Scler Relat Disord."},{"issue":"10","key":"495_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S1474-4422(24)00288-6","volume":"23","author":"L Amezcua","year":"2024","unstructured":"Amezcua L, Rotstein D, Shirani A, Ciccarelli O, Ontaneda D, Magyari M, et al. Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia. Lancet Neurol. 2024;23(10):1050\u201362.","journal-title":"Lancet Neurol"},{"issue":"10","key":"495_CR12","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"5","key":"495_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536\u201341.","journal-title":"JAMA Neurol"},{"issue":"4","key":"495_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307\u201316.","journal-title":"Lancet Neurol"},{"issue":"2","key":"495_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00415-021-10673-9","volume":"269","author":"K H\u00e4nninen","year":"2022","unstructured":"H\u00e4nninen K, Viitala M, Atula S, Laakso SM, Kuusisto H, Soilu-H\u00e4nninen M. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. J Neurol. 2022;269(2):913\u201322.","journal-title":"J Neurol"},{"key":"495_CR16","doi-asserted-by":"crossref","unstructured":"Mossburg S, Kilany M, Jinnett K, Nguyen C, Soles E, Wood-Palmer D, et al. A rapid review of interventions to improve care for people who are medically underserved with multiple sclerosis, diabetic retinopathy, and lung cancer. Int J Environ Res Public Health. 2024;21(5):529.","DOI":"10.3390\/ijerph21050529"},{"key":"495_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103734","volume":"61","author":"JR Abbatemarco","year":"2022","unstructured":"Abbatemarco JR, Carlson A, Ontaneda D, McGinley M, Bermel RA, Husak S, et al. Association of socioeconomic disadvantage and neighborhood disparities with clinical outcomes in multiple sclerosis patients. Mult Scler Relat Disord. 2022;61: 103734.","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"495_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40801-023-00387-x","volume":"10","author":"CK Geiger","year":"2023","unstructured":"Geiger CK, Sheinson D, To TM, Jones D, Bonine NG. Treatment patterns by race and ethnicity in newly diagnosed persons with multiple sclerosis. Drugs Real World Outcomes. 2023;10(4):565\u201375.","journal-title":"Drugs Real World Outcomes."},{"key":"495_CR19","unstructured":"TYSABRI\u00ae (natalizumab) [package insert], Biogen Inc, Cambridge, MA, USA."},{"issue":"9","key":"495_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"9","key":"495_CR21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"495_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/archneurol.2011.45","volume":"68","author":"BA Cree","year":"2011","unstructured":"Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011;68(4):464\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"495_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40120-023-00461-0","volume":"12","author":"J Perumal","year":"2023","unstructured":"Perumal J, Balabanov R, Balcer L, Galetta S, Sun Z, Li H, et al. Long-term effectiveness and safety of natalizumab in African American and Hispanic\/Latino patients with early relapsing-remitting multiple sclerosis: STRIVE data analysis. Neurol Ther. 2023;12(3):833\u201348.","journal-title":"Neurol Ther."},{"issue":"5","key":"495_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1017\/S1092852921000183","volume":"27","author":"J Avasarala","year":"2022","unstructured":"Avasarala J, Zachariah P, Turner B. Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity? CNS Spectr. 2022;27(5):527\u20139.","journal-title":"CNS Spectr"},{"issue":"9","key":"495_CR25","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","volume":"98","author":"HM Onuorah","year":"2022","unstructured":"Onuorah HM, Charron O, Meltzer E, Montague A, Crispino A, Largent A, et al. Enrollment of non-White participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review. Neurology. 2022;98(9):e880\u201392.","journal-title":"Neurology"},{"issue":"8","key":"495_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaneurol.2014.79","volume":"71","author":"J Avasarala","year":"2014","unstructured":"Avasarala J. Inadequacy of clinical trial designs and data to control for the confounding impact of race\/ethnicity in response to treatment in multiple sclerosis. JAMA Neurol. 2014;71(8):943\u20134.","journal-title":"JAMA Neurol"},{"key":"495_CR27","unstructured":"Komodo Health I. Healthcare Map\u2122: The Most Complete View of the Patient. 2024. https:\/\/www.komodohealth.com\/technology\/healthcare-map?utm_term=komodo%20health&utm_campaign=VSA-Brand&utm_source=adwords&utm_medium=ppc&hsa_acc=6595956088&hsa_cam=20727729965&hsa_grp=153740222583&hsa_ad=692116807630&hsa_src=g&hsa_tgt=aud-1287299728203:kwd-455792406478&hsa_kw=komodo%20health&hsa_mt=p&hsa_net=adwords&hsa_ver=3&gad_source=1&gclid=EAIaIQobChMIpfTO49jXiQMVm1ZHAR2LiSS9EAAYASABEgLNBvD_BwE. Accessed 12 Nov 2024."},{"key":"495_CR28","unstructured":"Congressional Research Service. Poverty in the United States in 2021. 2022. https:\/\/crsreports.congress.gov\/product\/pdf\/R\/R47354. Accessed 1 Jan 2025."},{"key":"495_CR29","doi-asserted-by":"publisher","first-page":"1197195","DOI":"10.3389\/fimmu.2023.1197195","volume":"14","author":"RA Marrie","year":"2023","unstructured":"Marrie RA, Fisk JD, Fitzgerald K, Kowalec K, Maxwell C, Rotstein D, et al. Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Front Immunol. 2023;14:1197195.","journal-title":"Front Immunol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00495-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00495-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:08:31Z","timestamp":1750129711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00495-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00495-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"2 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Biogen (Cambridge, MA, USA). Biogen provided funding for medical writing support (development of tables, figures, copyediting) in the development of this manuscript, and the decision to submit for publication. All authors had full access to study data, had full editorial control, and approved the final version. The corresponding author had final responsibility for the decision to submit for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K. Blitz-Shabbir: consultant fees from Biogen and Genentech; A. Banks and H. Garg: nothing to disclose; F. Nelson: consultant fee from Novartis; S. Shah: honoraria from Novartis and TG Therapeutics; N. Belviso, J.P. Mendoza, R.L. Avila, B. Bian, and K. Fong: employees of Biogen and may hold stock in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicting Interests"}},{"value":"This retrospective database analysis used de-identified claims data from the Komodo Health Claims Database in accordance with the Health Insurance Portability and Accountability Act to protect patient privacy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The analysis in this manuscript was based on claims data which precludes the capacity to obtain patients\u2019 consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The claims database details analyzed in this study are not publicly available as this is proprietary information. Researchers can purchase the data through a licensing agreement with Komodo Health.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and investigation: all; methodology, validation, and data curation: NB, JPM, RLA, BB, KF; supervision: KF, NB; writing and visualization of original draft: all; review and editing of drafts: all. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}}]}}